Skip navigation
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBrown, Stephen J.-
dc.contributor.authorGoetzmann, William N.-
dc.contributor.authorLiang, Bing-
dc.date.accessioned2008-05-28T16:20:19Z-
dc.date.available2008-05-28T16:20:19Z-
dc.date.issued2004-06-14-
dc.identifier.urihttp://hdl.handle.net/2451/26807-
dc.description.abstractFunds of funds are an increasingly popular avenue for hedge fund investment. Despite the increasing interest in hedge funds as an alternative asset class, the high degree of fund specific risk and the lack of transparency may give fiduciaries pause. In addition, many of the most attractive hedge funds are closed to new investment. Funds of funds resolve these issues by providing investors with diversification across manager styles and professional oversight of fund operations that can provide the necessary degree of due diligence. In addition, many such funds hold shares in hedge funds otherwise closed to new investment allowing smaller investors access to the most sought-after managers. However, the diversification, oversight and access comes at the cost of a multiplication of the fees paid by the investor. One would expect that the information advantage of funds of funds would more than compensate investors for these fees. Unfortunately, individual hedge funds dominate fund of funds on an after-fee return or Sharpe ratio basis. In this paper we argue that the disappointing after-fee performance of some fund of funds might be explained by the nature of this fee arrangement, and that fund of funds providers may actually benefit from considering other possible fee arrangements. These alternative arrangements will improve reported performance and may make funds of funds more attractive to a growing institutional clientele.en
dc.language.isoen_USen
dc.relation.ispartofseriesS-DRP-04-01en
dc.titleFees on Fees in Funds of Fundsen
dc.typeWorking Paperen
Appears in Collections:Derivatives Research

Files in This Item:
File Description SizeFormat 
S-DRP-04-01.pdf867.91 kBAdobe PDFView/Open


Items in FDA are protected by copyright, with all rights reserved, unless otherwise indicated.